Premium
Enhancement effects of a hepatocyte receptor—specific MR contrast agent in an animal model
Author(s) -
Small William C.,
Nelson Rendon C.,
Sherbourne Gillian M.,
Bernardino Michael E.
Publication year - 1994
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880040317
Subject(s) - contrast enhancement , hepatocyte , spleen , magnetic resonance imaging , contrast (vision) , bolus (digestion) , medicine , chemistry , nuclear medicine , radiology , biochemistry , computer science , in vitro , artificial intelligence
The enhancement characteristics of the liver and spleen produced by a hepatocyte‐specific magnetic resonance imaging agent, an arabinogalactan‐coated ultrasmall superparamagnetic iron oxide derivative, BMS 180550, were evaluated. Both heavily T1‐ and T2‐weighted sequences were used. Imaging was performed in the farm pig model, as a function of contrast agent concentration (5, 10, and 20 μmol of iron per kilogram) and delay (immediate, 0.5, 2.5, 5.0, 7.5, and 9.0 hours) after bolus injection of BMS 180550. BMS 180550 provided excellent contrast enhancement characteristics by producing marked positive enhancement with T1‐weighted sequences and marked negative enhancement with T2‐weighted sequences. The T1‐weighted enhancement immediately after contrast agent injection was of greater magnitude in the spleen (329% ± 83) than in the liver (66% ± 16). Postcontrast negative enhancement with T2‐weighted sequences was largely hepatocyte specific at 5 and 10 μmol/kg but was also seen within the spleen at 20 μmol/kg. The authors discuss the possible mechanisms that produce these changes and conclude that 10 μmol/kg BMS 180550 is near the optimum dose for maximizing the enhancement properties of this agent with all sequences in the farm pig.